Trial Profile
International Multicenter Comparative Randomized Double-blind Placebo-controlled Clinical Study of Efficacy and Safety of BCD-089 in Different Dosing Regimens in Patients With Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Levilimab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms AURORA
- Sponsors Biocad
- 06 Jun 2020 1 year Results presented at the 21st Annual Congress of the European League Against Rheumatism.
- 26 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2019 Primary endpoint (ACR20) has been met as per results presented at the 20th Annual Congress of the European League Against Rheumatism